All sponsors

BicycleTx Limited

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-30
RECRUITING1
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO50%

Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +11.0 months). See all sponsors →

Open BicycleTx Limited on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
BT7480
NCT05163041
P1/2Active, not recruitingAdvanced Solid Tumor2002026-08 (+11 mo)
BT5528
NCT04180371
P1/2Active, not recruitingAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer2882026-12-31 (+48 mo)
BT8009
NCT04561362
P1/2Active, not recruitingUrinary Bladder Neoplasm; Triple Negative Breast Neoplasms3292027-01 (+43 mo)
Zelenectide pevedotin
NCT06225596
P2Active, not recruitingMetastatic Urothelial Cancer3752028-03 (-33 mo)
Zelenectide pevedotin (BT8009)
NCT06840483
P2Active, not recruitingBreast Cancer662028-06-30
Zelenectide pevedotin
NCT06933329
P2Active, not recruitingNon-Small Cell Lung Cancer732028-08-31
nuzefatide pevedotin (BT5528)
NCT07450859
P2RecruitingPancreatic Ductal Adenocarcinoma (PDAC)392029-03
Zelenectide pevedotin
NCT07681674
P2Not yet recruitingAdvanced Solid Tumors162030-05-30